CVS Health Corporation (CVS) – Strong revenue growth

CVS Health Corporation (CVS) (Q2FY23)

Stock Performance – CVS Health Corporation stock price showed a volatile trend in past 3-months. It declined by 0.75% during the period. The price declined by 31.11% in past 1-year. It has a 52-week high of $104.83 and its 52-week low is $64.62.

In the past 3 years, the stock has given returns of 19.75%. CVS has a 50-day moving Avg. and 200-day moving Avg. of $70.19 and $75.85, respectively.

Revenue Performance – CVS revenues increased 10.3% driven by growth across all segments. Total revenues increased $16.7bn, or 10.6%, in the six months ended June 30, 2023 compared to the prior year.

Company Guidance for FY23 – GAAP diluted EPS is expected to be $6.53 to $6.75. Adjusted EPS guidance range of $8.50 to $8.70. Cash flow from operations is expected to be $12.5bn to $13.5bn.

Highlights

The company has experienced a notable increase in membership, indicating widespread growth. This growth includes the eighth consecutive quarter of gains in their commercial sector. Furthermore, they have expanded their individual offerings into 12 states, demonstrating their commitment to expanding and diversifying their services to reach a broader audience and sustain their growth trajectory.

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Metrics
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages: 35

To download the previous quarter’s equity/ stock report CLICK HERE

To Download other equity/ stock reports CLICK HERE

Follow our LinkedIn page for more updates.